Antibacterial activity of trovafloxacin against gram-positive blood culture isolates from nosocomial infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 8, 1996, Pages 694-696

  Qadri, S M Hussain ^a   Ueno, Y ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; ENOXACIN; NORFLOXACIN; OFLOXACIN; PENICILLIN G; TROVAFLOXACIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029818220     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691163     Document Type: Article

References (10)

1. Siporin C: The evolution of fluorinated quinolones: pharmacology, microbial activity, clinical uses, and toxicities. Annual Review of Microbiology 1989, 43: 601-627.
2. Baron JE, Peterson LR, Finegold SM; BaileyéScott's Diagnostic Microbiology. Mosby-Year Book Inc., London, 1994, p. 321-352.
3. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7A3. NCCLS, Villanova, PA, 1993.
4. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Toison J, Henderson T, Martone WJ, and the National Nosocomial Infections Surveillance System: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. American Journal of Medicine 1991,91, Supplement 3B: 86-89.
5. Finegold SM, Baron EJ: Diagnostic microbiology. CV Mosby, St. Louis, 1991.
6. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia; attributable mortality and excess length of stay. Archives of Internal Medicine 1988, 148: 2642-2647.
7. Martin MA, Pfaller MA, Wenzel RP: Coagulase-negative staphylococcal bacteremia: mortality and hospital stay. Annals of Internal Medicine 1989, 110: 9-16.
8. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In-vitro activity of CP-99,219, a new fiuoroquinolone, against clinical isolates of gramnegative bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366-370.
9. Gootz RD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: Invitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Diseases 1994, 19: 235-243.
10. Qadri SMH, Cunha BA, Ueno Y, Kayes S, Postle AG: Etiology of nosocomial infections and the susceptibility of nosocomial pathogens to imipenem and other antimicrobial agents at a tertiary care referral hospital. Current Therapeutic Research 1995, 56: 746-755.